Quality of life in patients treated with aflibercept and FOLFIRI for metastatic colorectal cancer: interim analysis with focus on therapy lines of the non -interventional study QoLiTrap (AlO-LQ-0113)

被引：0
|
作者：
Hofheinz, R. [1 ]
Scholten, F. [2 ]
Derigs, H. [2 ]
Thaler, J. [3 ]
von Moos, R. [1 ,4 ]
机构：
[1] Univ Hosp Mannheim, Mannheim, Germany
[2] Klinikum Frankfurt Hoechst GmbH, Frankfurt, Germany
[3] Klinikum Wels Grieskirchen GmbH, Wels, Austria
[4] Kantonsspital Graubuenden, Chur, Switzerland
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD - 026
引用
收藏
页码：118 / 118
页数：1
相关论文
共 50 条
  • [21] Non-interventional study in elderly patients with metastatic colorectal cancer treated with first line bevacizumab combined to chemotherapy in real life: The CASSIOPEE Study - Interim analysis on patients' characteristics
    Cois, E. Fran
    Kim, S.
    Deplanque, G.
    Smith, D.
    Gourgou, S.
    Rollot-Trad, F.
    Gally, S.
    Berthier, A.
    Mineur, L.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S336 - S336
  • [22] Aflibercept in combination with FOLFIRI for the second-line treatment of patients with metastatic colorectal cancer: Interim safety data from the global Aflibercept Safety and Quality-of-Life Program (ASQoP and AFEQT studies)
    Sobrero, A.
    Bordonaro, R.
    Frassineti, L.
    Di Bartolomeo, M.
    Thomas, A. L.
    Taieb, J.
    Lledo, G.
    Moore, Y.
    Zilocchi, C.
    Ferry, D. R.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S521 - S521
  • [23] A VELOUR post hoc subset analysis: prognostic groups and treatment outcomes in patients with metastatic colorectal cancer treated with aflibercept and FOLFIRI
    Ian Chau
    Florence Joulain
    Sheikh Usman Iqbal
    John Bridgewater
    BMC Cancer, 14
  • [24] A VELOUR post hoc subset analysis: prognostic groups and treatment outcomes in patients with metastatic colorectal cancer treated with aflibercept and FOLFIRI
    Chau, Ian
    Joulain, Florence
    Iqbal, Sheikh Usman
    Bridgewater, John
    BMC CANCER, 2014, 14
  • [25] Quality of life (QoL) in patients with metastatic castration resistant prostate cancer (mCRPC) treated with cabazitaxel: Interim analysis of a prospective non-interventional trial (QoLiTime)
    Hofheinz, R.
    Al-Batran, S. E.
    Hammerer, P.
    Kienitz, C.
    Kloss, S.
    Lange, C.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S700 - S700
  • [26] Quality of life analysis in patients with RAS wild-type metastatic colorectal cancer treated with first-line FOLFIRI plus cetuximab in the CRYSTAL study
    Yamaguchi, K.
    Ando, M.
    Ooki, A.
    Beier, F.
    Guenther, S.
    Von Hohnhorst, P.
    Van Cutsem, E.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S370 - S371
  • [27] Aflibercept (afl) in combination with FOLFIRI for the 2nd-line treatment of patients (pts) with metastatic colorectal cancer (mCRC): Interim safety and quality-of-life (QoL) data from the Italian subgroup of the Aflibercept Safety and Quality-of-Life Program (ASQoP)
    Bordonaro, R.
    Passardi, A.
    Fasola, G.
    Ciuffreda, L.
    Di Bartolomeo, M.
    Siena, S.
    Di Costanzo, F.
    Fornarini, G.
    Cordio, S.
    Sobrero, A.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S513 - S513
  • [28] QUALITY OF LIFE ANALYSIS IN PATIENTS WITH KRAS WILD-TYPE METASTATIC COLORECTAL CANCER TREATED WITH FIRST-LINE FOLFIRI PLUS CETUXIMAB
    Lang, I.
    Koehne, C.
    Folprecht, G.
    Rougier, P.
    Curran, D.
    Hitre, E.
    Sartorius, U.
    Griebsch, I.
    Van Cutsem, E.
    ANNALS OF ONCOLOGY, 2012, 23 : 191 - 192
  • [29] 1st-line panitumumab plus FOLFIRI or FOLFOX for patients with RAS wildtype metastatic colorectal cancer in Germany: Interim results of the non-interventional study VALIDATE
    Uhlig, J.
    Potenberg, J.
    Semsek, D.
    Stuebs, P.
    Fichter, C. D.
    Koehler, A.
    Mueller, L.
    Reiser, M.
    Siebenbach, H. U.
    Goehler, T.
    Jacobasch, L.
    Kaechele, V.
    Timm, B.
    Potthoff, K.
    Marschner, N. W.
    ANNALS OF ONCOLOGY, 2020, 31 : S436 - S436
  • [30] Post hoc safety and effectiveness analysis of aflibercept plus FOLFIRI for patients with metastatic colorectal cancer (mCRC) previously treated with antiepidermal growth factor receptor (EGFR) therapy in OZONE
    Cartwright, Thomas H.
    Fakih, Marwan
    Garcia-Alfonso, Pilar
    Linke, Zdenek
    Ruiz Casado, Ana
    Polo Marques, Eduardo
    Picard, Pascaline
    Celanovic, Marina
    Singh, Arvind Rup
    Salinardi, Taylor
    Chau, Ian
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
12345